{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:29:44Z","timestamp":1792193384398,"version":"4.4.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Aortic valve dysfunction is a rare but relevant long-term complication after orthotopic heart transplantation (HTX). Treatment options include surgical (SAVR) and transcatheter (TAVR) aortic valve replacement, but evidence is limited to the level of case reports.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A total of 2054 patients underwent HTX between 1986 and 2023 at the Deutsches Herzzentrum der Charit\u00e9, Berlin, Germany, 16 of them underwent aortic valve replacement (SAVR, N\u2009=\u20097; TAVR, N\u2009=\u20099) after HTX. In this case series we report on the outcomes of these 16 patients (age 29-73 years).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Isolated aortic valve regurgitation occurs in 5 (31%) patients (TAVR N\u2009=\u20091, SAVR N\u2009=\u20094), while 11 patients (69%) suffer from aortic valve stenosis. Severe pre-procedural heart failure is present in 38% of the patients. Thirty-day mortality is 0%, in-hospital mortality is N\u2009=\u20092 (22%) patients due to sepsis, both patients were severely decompensated prior to TAVR. An uneventful postoperative course occurs in 8 (50%) patients, the patient\u2019s functional status improves in 12 (75%) cases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>TAVR is the increasingly preferred treatment for aortic valve dysfunction after heart transplantation, but SAVR is a feasible alternative for individuals who are ineligible for TAVR. Further information is needed on the appropriate procedural timing in these high-risk patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s43856-025-01151-8","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:30:32Z","timestamp":1759318232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Surgical and transcatheter aortic valve replacement after orthotopic heart transplantation: a case series"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-075X","authenticated-orcid":false,"given":"Luise","family":"Roehrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9602-2794","authenticated-orcid":false,"given":"Hristian","family":"Hinkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8127-5019","authenticated-orcid":false,"given":"Christoph","family":"Knosalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hennig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Kukucka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Merke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurenz","family":"Kopp Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell Anna","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1909-4329","authenticated-orcid":false,"given":"Henryk","family":"Dreger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7911-8620","authenticated-orcid":false,"given":"Volkmar","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Unbehaun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Schoenrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"1151_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"1151_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/phar.2716","volume":"42","author":"J Nelson","year":"2022","unstructured":"Nelson, J. et al. Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation. Pharmacotherapy 42, 599\u2013633 (2022).","journal-title":"Pharmacotherapy"},{"key":"1151_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.5606\/tgkdc.dergisi.2024.25631","volume":"32","author":"O Yilmaz","year":"2024","unstructured":"Yilmaz, O. & Keenan, N. M. Management options of valvular heart diseases after heart transplantation: a scoping review. Turk. Gogus Kalp Damar Cerrahisi Derg. 32, 112\u2013122 (2024).","journal-title":"Turk. Gogus Kalp Damar Cerrahisi Derg."},{"key":"1151_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2021","unstructured":"Vahanian, A. et al. 2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 43, 561\u2013632 (2021).","journal-title":"Eur. Heart J."},{"key":"1151_CR5","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2400685","volume":"390","author":"S Blankenberg","year":"2024","unstructured":"Blankenberg, S. et al. Transcatheter or surgical treatment of aortic-valve stenosis. N. Engl. J. Med. 390, 1572\u20131583 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1151_CR6","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/eurheartj\/ehae043","volume":"45","author":"HGH Thyregod","year":"2024","unstructured":"Thyregod, H. G. H. et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur. Heart J. 45, 1116\u20131124 (2024).","journal-title":"Eur. Heart J."},{"key":"1151_CR7","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1008232","volume":"363","author":"MB Leon","year":"2010","unstructured":"Leon, M. B. et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N. Engl. J. Med. 363, 1597\u20131607 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1151_CR8","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1053\/j.jvca.2017.12.015","volume":"32","author":"A Belletti","year":"2018","unstructured":"Belletti, A. et al. Incidence and predictors of postoperative need for high-dose inotropic support in patients undergoing cardiac surgery for infective endocarditis. J. Cardiothorac. Vasc. Anesthesia 32, 2528\u20132536 (2018).","journal-title":"J. Cardiothorac. Vasc. Anesthesia"},{"key":"1151_CR9","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.jacc.2021.02.038","volume":"77","author":"P G\u00e9n\u00e9reux","year":"2021","unstructured":"G\u00e9n\u00e9reux, P. et al. Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research. J. Am. Coll. Cardiol. 77, 2717\u20132746 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1151_CR10","unstructured":"Wenn P., Zeltser R. Aortic Valve Disease. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2024 (StatPearls Publishing, 2024)."},{"key":"1151_CR11","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10741-023-10368-5","volume":"29","author":"B Cuko","year":"2024","unstructured":"Cuko, B. et al. Outcomes of left-sided heart valve surgery after heart transplantation: a systematic review. Heart Fail Rev. 29, 227\u2013234 (2024).","journal-title":"Heart Fail Rev."},{"key":"1151_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2021.100672","volume":"36","author":"AM Jordan","year":"2022","unstructured":"Jordan, A. M. et al. Infective endocarditis following heart transplantation: a systematic review. Transpl. Rev. 36, 100672 (2022).","journal-title":"Transpl. Rev."},{"key":"1151_CR13","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1093\/eurheartj\/ehac105","volume":"43","author":"S Windecker","year":"2022","unstructured":"Windecker, S. et al. Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation? Eur. Heart J. 43, 2729\u20132750 (2022).","journal-title":"Eur. Heart J."},{"key":"1151_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2405880","volume":"392","author":"P G\u00e9n\u00e9reux","year":"2025","unstructured":"G\u00e9n\u00e9reux, P. et al. EARLY TAVR trial investigators. Transcatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N. Engl. J. Med. 392, 217\u2013227 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1151_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.tcm.2023.10.003","volume":"34","author":"B Cuko","year":"2024","unstructured":"Cuko, B. et al. Transcatheter valvular interventions after heart transplantation: a systematic review. Trends Cardiovasc Med. 34, 362\u2013368 (2024).","journal-title":"Trends Cardiovasc Med."},{"key":"1151_CR16","doi-asserted-by":"publisher","first-page":"ezaf191","DOI":"10.1093\/ejcts\/ezaf191","volume":"67","author":"H Hinkov","year":"2025","unstructured":"Hinkov, H. et al. Transcatheter management of left-sided valvular heart disease following heart transplantation. Eur. J. Cardiothorac. Surg. 67, ezaf191 (2025).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"1151_CR17","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/S0140-6736(18)32555-8","volume":"393","author":"DR Spahn","year":"2019","unstructured":"Spahn, D. R. et al. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial.  Lancet 393, 2201\u20132212 (2019).","journal-title":"Lancet"},{"key":"1151_CR18","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1093\/ejcts\/ezs043","volume":"41","author":"SA Nashef","year":"2012","unstructured":"Nashef, S. A. et al. EuroSCORE II. Eur. J. Cardiothorac. Surg. 41, 734\u2013744 (2012).","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"1151_CR19","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.athoracsur.2018.03.003","volume":"105","author":"SM O\u2019Brien","year":"2018","unstructured":"O\u2019Brien, S. M. et al. The society of thoracic surgeons 2018 adult cardiac surgery risk models: part 2-statistical methods and results. Ann. Thorac. Surg. 105, 1419\u20131428 (2018).","journal-title":"Ann. Thorac. Surg."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01151-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01151-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01151-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:30:33Z","timestamp":1759318233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01151-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1151"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01151-8","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"31 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The following authors declare no competing interests: L.R., H.H.i., C.K., F.H., C.K.l., M.K., N.M., L.K.F. The authors declare the following competing interests outside of the submitted work: I.A.J. Speakers honoraria from astrazeneca, Abbott, Abiomed. S.O. received institutional research and study funds from Novartis Pharma GmbH and institutional research, study and educational grants, speaker fees and advisory board fees from Abiomed. H.D. Speaker\u2019s fees, advisory board: Abbott, Edwards; research support: Abbott. V.F. institutional financial activities in relation to the following: educational grants (including travel support), fees for lectures and speeches, fees for professional consultation, and research and study funds with the following commercial entities: Medtronic GmbH, Biotronik S.E. & Co, Abiomed GmbH, Abbott GmbH & Co, KG, Boston Scientific, Edwards Lifesciences, Berlin Heart, Novartis Pharma GmbH, JOTEC\/CryoLife GmbH, LivaNova, and Zurich Heart. A.U. Physician proctor to Edwards Lifesciences, Medtronic and JenaValve. F.S. received institutional grants from Novartis, Abbott, non-financial support from Medtronic and institutional fees (speaker honoraria) from Abbott, Bayer, Novartis and Abiomed outside of the submitted work","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"412"}}